CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 258 enrolled
Drug / intervention
Fentanyl +1 moredrug
Likely dose
Fentanyl 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01008553
NCT01008553Phase 3Completed
CompareCT.gov

A Verification Study of JNS020QD in Patients With Post-herpetic Neuralgia, Complex Regional Pain Syndrome (CRPS) or Postoperative Pain Syndrome

Janssen Pharmaceutical K.K.·interventional·Posted Nov 6, 2009·Updated Jul 25, 2013

In Brief

A Phase 3 clinical trial evaluating Fentanyl and Placebo for Postherpetic Neuralgia and 2 related conditions. Completed, enrolled 258 participants across 79 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of fentanyl in opioid-naive participants with post-herpetic neuralgia, complex regional pain syndrome or post-operative pain syndrome who cannot obtain a sufficient analgesic effect by the treatment of non-opioid analgesics (drug used to control pain).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostherpetic Neuralgia, Complex Regional Pain Syndromes (CRPS), Postoperative Pain
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 6, 2009
Enrollment StartDec 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.7 years ago

Interventions

Fentanyldrug

One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.

Placebodrug

Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.